Genevant’s leadership in nucleic acid delivery is reflected in a number of peer-reviewed publications authored by our scientists, alone or in collaboration with other researchers.

Lam, et al. (2023)

Optimizing Lipid Nanoparticles for Delivery in Primates

Advanced Materials


Lam, et al. (2023)

Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid-Nanoparticle Components for Therapeutic and Vaccine Applications

Advanced Materials


Ye, et al. (2023)

Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection

Molecular Therapy

Gatechompol (2022)

Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial

Nature Microbiology

DOI: 10.1038/s41564-022-01271-0

Prompetchara, et al. (2022)

Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice

Nature Communications

DOI: 10.1038/s41467-023-37795-0

Muramatsu, et al. (2022)

Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine

Molecular Therapy

DOI: 10.1016/j.ymthe.2022.09.009

Parhiz, et al. (2022)

Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)

Journal of controlled Release

DOI: 10.1016/j.jconrel.2021.12.027

Holland, et al. (2021)

Ligand conjugate SAR and enhanced delivery in NHP

Molecular Therapy